Evidence map›Paper›PMID 42519330›Full record

ReviewFrontiers in immunology2026

From exhaustion to functional cure: frontiers in reversing HBV-specific T-cell immunity.

Lifen Liang, Xiangping Xie, Shuangyan He, Liang Zhou, Yehong Yue

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lifen LiangDepartment of Infectious Disease, Shaoyang Central Hospital, Shaoyang, China.
Xiangping XieDepartment of Infectious Disease, Shaoyang Central Hospital, Shaoyang, China.
Shuangyan HeDepartment of Infectious Disease, Shaoyang Central Hospital, Shaoyang, China.
Liang ZhouDepartment of General Medicine, the Second Affiliated Hospital of Wannan Medical College, Wuhu, China.
Yehong YueDepartment of Infectious Disease, Shaoyang Central Hospital, Shaoyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic hepatitis B (CHB) remains a leading cause of liver-related morbidity and mortality, affecting approximately 254 million people worldwide and accounting for more than 800,000 deaths annually. Although nucleos(t)ide analogues (NAs) durably suppress viral replication, the annual rate of HBsAg loss is only ~1%, leaving functional cure as the foremost unmet clinical need. Exhaustion of HBV-specific CD8

Indexed as

CD8-Positive T-LymphocytesHepatitis B, ChronicHepatitis B virusAnimalsEpigenesis, GeneticHost-Directed TherapyHumansT-Cell Exhaustionchronic hepatitis Bcombination therapyepigenetic reprogrammingfunctional cureimmune checkpoint blockademetabolic rewiringT-cell exhaustionTOX

Identifiers

PMID42519330
PMCPMC13381426

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.